about
Exercise for cancer cachexia in adultsPharmacology of manipulating lean body massCachexia and pancreatic cancer: are there treatment options?Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulationMolecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-negative breast cancer.JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.Molecular and cellular mechanisms of skeletal muscle atrophy: an update.Consilience in sarcopenia of cirrhosis.Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wastingNotch Signaling Mediates Skeletal Muscle Atrophy in Cancer Cachexia Caused by Osteosarcoma.Isotopic decay of urinary or plasma 3-methylhistidine as a potential biomarker of pathologic skeletal muscle loss.Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responsesMyostatin inhibitors as therapies for muscle wasting associated with cancer and other disordersThe emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue.Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.Myostatin gene mutated mice induced with tale nucleases.Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases.Human skeletal muscle fibre contractile properties and proteomic profile: adaptations to 3 weeks of unilateral lower limb suspension and active recovery.Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle
P2860
Q24187827-7F14A632-7821-4BF3-ACF7-EC60BEE1C92AQ26824503-BA87DBE4-DA7C-4E23-B986-1A5AF4F44C6DQ27026558-30DF9A77-2483-4C8F-869C-5B3387185A69Q27312755-6A48A6C4-4695-48E0-8FF8-002D4F690F54Q28068034-E121085A-9FCB-4613-9A01-8BF8268B7F67Q35759017-45CCD083-3DC9-4AC4-AF8F-15F314852B38Q36176015-A7413CD6-D6EA-4B7F-BB78-1822501F7CE0Q36179105-0C14A41C-B3C9-4EE5-BFF8-26A1D33FB74AQ36421047-1C80B391-2515-4CE1-B319-C4A02813CD34Q36686835-AF60B031-1253-408A-A0BB-97C2E20390ADQ37030454-5894FE88-442E-4434-A8A2-358058F7EAABQ37635905-45EBCDB0-5DC0-4D5F-AF9D-B6C8E9CBD408Q37982868-052CF44B-4D6E-42B2-B094-5F2A903D1D03Q38155361-CA176D38-F894-463F-8977-BCB1C7A35FC4Q38670238-E2484B8C-1934-41D6-80B6-5A5680B4C7F6Q38865410-29554C10-B389-4D8E-8831-B5685A35F688Q40640594-1977421F-FDF7-4DE1-88AA-40D9F732F44BQ41391834-A2EA420D-D86E-4A11-BE14-9E64C1EDE582Q41825244-45227088-0E96-4C3B-8712-1E2EC104C208Q52917126-C53734E7-F7A4-4B8E-80FF-77BD5D7CB70CQ55432588-D8DD20AA-F21D-40B4-800F-EC99DBCE2900Q57278903-269AF080-3B9C-4DBD-9AF5-FF3CF3C71C72
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treating cancer cachexia to treat cancer
@ast
Treating cancer cachexia to treat cancer
@en
type
label
Treating cancer cachexia to treat cancer
@ast
Treating cancer cachexia to treat cancer
@en
prefLabel
Treating cancer cachexia to treat cancer
@ast
Treating cancer cachexia to treat cancer
@en
P2860
P356
P1433
P1476
Treating cancer cachexia to treat cancer
@en
P2093
David J Glass
Se-Jin Lee
P2860
P2888
P356
10.1186/2044-5040-1-2
P577
2011-01-24T00:00:00Z
P5875
P6179
1025365939